A Placebo-controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of Ascending Doses of XT-150 for the Treatment of Osteoarthritic Pain
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Oct 2018
At a glance
- Drugs XT-150 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; First in man
- Sponsors Xalud Therapeutics
- 28 Sep 2018 Planned End Date changed from 28 Feb 2019 to 28 Mar 2019.
- 28 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2018 Planned End Date changed from 30 Dec 2018 to 28 Feb 2019.